ST. LOUIS, Oct. 9, 2026 /PRNewswire/ -- The board of directors of Ameren Corporation (NYSE: AEE) today declared a quarterly cash dividend on its common stock of 75 cents per share. This dividend is payable Dec. 31, 2026, to shareholders of record at the close of business on Dec. 8, 2026.

Separately, the board of directors of Union Electric Company, doing business as Ameren Missouri, declared regular quarterly cash dividends on all classes of Union Electric Company's preferred stock. These preferred stock dividends are payable Feb. 15, 2027, to shareholders of record at the close of business on Jan. 14, 2027.

In addition, the board of directors of Ameren Illinois Company, doing business as Ameren Illinois, declared regular quarterly cash dividends on all classes of Ameren Illinois Company's preferred stock. These preferred stock dividends are payable Feb. 1, 2027, to shareholders of record at the close of business on Jan. 8, 2027.

About Ameren Corporation

St. Louis-based Ameren Corporation powers the quality of life for 2.5 million electric customers and more than 900,000 natural gas customers in a 64,000-square-mile area through its Ameren Missouri and Ameren Illinois rate-regulated utility subsidiaries. Ameren Illinois provides electric transmission and distribution service and natural gas distribution service. Ameren Missouri provides electric generation, transmission and distribution services, as well as natural gas distribution service. Ameren Transmission Company of Illinois develops, owns and operates rate-regulated regional electric transmission projects in the Midcontinent Independent System Operator, Inc. For more information, visit Ameren.com, or follow us at @AmerenCorp, Facebook.com/AmerenCorp, or LinkedIn.com/company/Ameren. 

SOURCE Ameren Corporation

Share this article

Self-improving cybersecurity LLMs do offense–defense interplay in customizable on-prem deployments and run at massively lower cost.

PALO ALTO, Calif., Oct. 9, 2026 /PRNewswire/ -- Lean SuperIntelligence (LSI) is the first AI lab to build self-improving offense and defense security LLMs that enable enterprises to stay ahead of attackers without renting out their data to the cloud. The two models improve each other: LSI-Offense-1 LLM finds, exploits, and validates vulnerabilities and LSI-Defense-1 LLM detects, investigates, and responds within minutes, not days to weeks. Inside LSI's Cyber World Models, every attack the offense finds becomes a lesson for the defense, and every defense that holds forces the offense to find a new path, so both models keep getting better on customers' own data. Customizable and air-gapped, they beat frontier LLMs at vulnerability discovery and threat detection, and they are lean enough to run continuously, scanning every check-in software developers make. LSI's pre-seed round is backed by leading investors and angels who have led AI and security at OpenAI, CrowdStrike, SentinelOne, Zscaler, Commvault, and Gruve AI.

Outperforming frontier models on offense and defense

On independent, real-world offense security benchmarks, LSI-Offense-1 LLM significantly outperforms frontier models including Claude Mythos™, GPT-6 and Gemini-3.8-Cyber at autonomously discovering, exploiting and validating vulnerabilities. The model has already uncovered previously unknown vulnerabilities. The results show that specialized, lean cybersecurity models can exceed general-purpose frontier models.

On public defense benchmarks spanning multi-step threat detection, investigation, and response, LSI-Defense-1 LLM significantly outperforms frontier models from the same labs at a fraction of their cost, triaging alerts, correlating telemetry, and returning verdicts in seconds with far fewer false positives.

Why it matters

- Attacks move in minutes. A rumoured vulnerability becomes a working exploit in under 10 minutes; defense must keep pace on every event.

- Enterprises want to own, not rent. Today they send code and telemetry to frontier labs, pay hundreds of millions in inference, and own nothing they learn. That's why two-thirds of enterprises moved AI workloads back on-prem last year,[1] and sovereign cloud spending hits $80B in 2026.[2]

LSI gives enterprises self-improving security models they own.

Founded by the team behind National / Sovereign LLMs, the first AI Guardrails, AI labs at Alexa, Uber AI and Salesforce Research — and elite security experts.

- Chandra Khatri, Founder and CEO of LSI, with more than 50 patents and publications, was Founding Head of AI at Krutrim, where he built India's first sovereign LLM in 2023. He co-founded Got It AI, where he built ELMAR, the first enterprise LLM, and TruthChecker, the world's first hallucination guardrails model (acquired). He led AI initiatives at Uber AI, Amazon Alexa AI, and eBay Research.

- LSI's founding engineers have built sovereign AI and foundation models end to end, from pre-training data to production deployment to 10s of millions of users.

- LSI's founding security team has discovered hundreds of critical CVEs for major organizations and national intelligence agencies.

Comments

"You cannot defend against an attack you have never seen. So we trained the Offense LLM first," said Chandra Khatri, Founder and CEO of LSI. "Our LSI-Offense-1 LLM is built to be a generation ahead of the attacks in the wild, and our LSI-Defense-1 LLM learns from every attack LSI-Offense-1 finds. Frontier labs give everyone the same model. We provide each enterprise its own customizable model, running on-premise and trained on its own private data."

"Chandra has spent his career building at each major wave of AI — Alexa, Uber AI, enterprise LLMs and guardrails at Got It AI, and India's first sovereign LLM. LSI is the natural next step." — Lu Zhang, Founder & Managing Partner, Fusion Fund

Availability

LSI-Offense-1 and LSI-Defense-1 LLMs are available now to a limited number of design partners (security vendors, MSSPs, and certain Fortune 500 enterprises) for air-gapped, on-prem, sovereign, or managed deployment. Request access at lsi.inc.

About LSI

Lean SuperIntelligence (LSI) is the first lab building self-improving offense and defense security LLMs, on the path to Security SuperIntelligence. Founded by Chandra Khatri (Krutrim, Got It AI, Amazon Alexa, Uber AI), LSI brings together sovereign and enterprise LLM builders and expert security researchers.

Follow LSI: LinkedIn, X/Twitter

Claude Mythos is a trademark of Anthropic PBC. All other trademarks are the property of their respective owners.

References

- 66% of enterprises repatriated AI workloads from public cloud, survey of 1,500 enterprise architects, June 2026.

- Worldwide sovereign cloud IaaS spending to total $80 billion in 2026, February 2026.

Media contact

SOURCE LSI Inc.

Share this article

Americans with Kidney, Cardiac, and Metabolic Disorders Target Barriers to Care Choice

Newly Registered Voters Motivated by Medical Innovation and Living Organ Donor Protections

WASHINGTON, Oct. 9, 2026 /PRNewswire/ -- The American Association of Kidney Patients (AAKP), the nation's oldest and largest independent kidney patient advocacy organization, today marked the midpoint of its 2026 national, nonpartisan KidneyVoter™ campaign, "50 States in 50 Days." Launched on September 14, 2026, the campaign has successfully engaged and mobilized key constituencies across 25 states. The campaign engages kidney patients, living organ donors, families, care partners, advocates, researchers, healthcare professionals, and employees of small and large companies involved in kidney, heart, and diabetes care innovation. The 2026 effort has also reached patient and professional communities impacted by Cardio-Kidney-Metabolic (CKM) Syndrome and includes heart disease advocates, the diabetes community, and patients suffering from bone and mineral disorders

Kidney disease impacts more than 37 million Americans and their families. Further, interrelated cardiovascular, kidney, and metabolic diseases have impacted more than 25% of the adult population and are a leading cause of death. More broadly, an estimated 90% of U.S. adults, or approximately 240 million people, have some degree of interconnected cardiovascular, kidney, or metabolic health conditions according to the American Heart Association.

For the remainder of October, the KidneyVoter™ campaign will focus on states with populations highly impacted by the burdens of multiple chronic diseases, including Maine, Texas, New Hampshire, Michigan, North Carolina, Georgia, Montana, Florida, Washington, Iowa, and others. AAKP's 2026 strategy incorporates tactics refined during its successful 2024 KidneyVoter™ program that engaged over 500,000 KidneyVoters™. According to election data science and targeting experts, the 2024 campaign created a new "micro-constituency" within the American electorate. By the 2028 election cycle, AAKP estimates the KidneyVoter™ program will engage over one million Americans impacted by kidney and other chronic diseases and organ failure.

AAKP President Edward V. Hickey, III, a chronic kidney disease patient, stated, "At the midpoint of our 2026 nonpartisan voter registration campaign, it is clear that the people AAKP has engaged are highly motivated voters. They are determined to send a message to every candidate that issues affecting their health, and the health of their loved ones, are too often overlooked. Those issues include permanently protecting the jobs of living organ donors under the FMLA, speeding FDA approval of a new generation of safer transplant medicines, and adopting common-sense Medicare payment reforms so patients can get life-saving innovations while they still have time to benefit." Hickey is a U.S. Marine Corps Veteran, a former senior Congressional aide, and has served in appointed roles in two presidential administrations. He currently serves on the American Board of Internal Medicine's (ABIM) Nephrology Specialty Board and as the Chair of the AAKP Veterans Health Initiative, the largest kidney health outreach program outside of the U.S. Department of Veterans Affairs.

KidneyVoters™ use their social media networks, voices, and votes to bring Congressional and White House attention to issues that undermine America's efforts to save more innocent lives from chronic diseases and to reduce health spending. Top issues include the lack of kidney and chronic disease awareness and prevention, long-overdue early disease screening, anti-competitive practices of America's large corporate dialysis providers, utilization of discriminatory Quality-Adjusted Life Year (QALY) measures, and negative Government Determinants of Health (GDOH) including obsolete federal regulations and Medicare reimbursement policies that stymie innovation and patient choice of new treatments. In 2024, AAKP patient advocates led the kidney community by calling for the immediate dismissal of the U.S. Preventive Services Task Force (USPSTF) leadership, citing USPSTF's 20-year record of incompetence and failure to issue a screening recommendation for kidney disease for the most vulnerable Americans. The USPSTF failure occurred despite USPSTF's access to overwhelming peer-reviewed evidence of the dangers of disease progression, high mortality rates among organ failure patients, increased utilization of taxpayer-funded dialysis, and growing demand for donated organs. AAKP has expressed strong support for Health and Human Services Secretary Robert F. Kennedy's recent appointments to the USPSTF of specialists familiar with interrelated heart, kidney, and metabolic issues.

AAKP Vice President and Chair of Policy and Global Affairs Paul T. Conway, a 49-year kidney patient and 29-year transplant recipient, stated, "People impacted by multiple chronic diseases, including kidney disease, understand the role elected and appointed leaders play in their personal health, science, and medical innovation as well as the availability of new, lifesaving diagnostics and treatments. They are sophisticated healthcare consumers and reject the idea of paying for avoidable medical interventions, with their own money or taxpayer funds, when new technologies allow for earlier disease detection and treatment and the avoidance of emergencies that jeopardize lives and livelihoods. Across the nation, from Maine to Washington, patients and families are angry with political leaders and medical elites that appear more committed to defending special interests and paternalistic systems than solving the everyday health needs of people and the frontline doctors they trust." Conway is a former Chief of Staff of the U.S. Department of Labor and a former Deputy Secretary for Health and Human Resources for Virginia. He is the past Chair of the U.S. Food and Drug Administration's Patient Engagement Advisory Committee (PEAC) and a member of the American Diabetes Association's Kidney Disease Workgroup.

AAKP has leveraged the KidneyVoter™ program to educate people nationwide on the plight of those awaiting organ transplants and the overwhelming need to increase living organ donation. Increased living organ donation, improved transplant readiness, and greater opportunities for transplantation are national goals reinforced in 2019 through President Donald Trump's bipartisan Executive Order on Advancing American Kidney Health. AAKP, alongside a broad coalition of patient organizations, transplant experts, and Congressional allies, is working to secure passage of the bipartisan Living Donor Protection Act (LDPA), S. 1552/H.R. 4582 and H.R. 4583. The legislation protects living organ donors from job and insurance discrimination based solely on their decision to donate a kidney to save another life, barriers cited most often by potential organ donors. The bipartisan bill is led by Senator Tom Cotton (R-AK) and Senator Kirsten Gillibrand (D-NY). It was voted out of the Senate HELP Committee on February 26, 2026, with full bipartisan support, the endorsement of AAKP, the united kidney community, and the American Council of Life Insurance (ACLI).

In 2018, with bipartisan support from Congress and the Trump Administration, AAKP and transplant professionals worked with the U.S. Department of Labor's (DOL) legal team and the DOL Wage and Hour Division to have DOL extend Family and Medical Leave Act (FMLA) protections for living organ donors, based on the original intent of the FMLA's Congressional co-sponsors (click here to read the letter and click here to watch the video). Congressional passage of the LDPA in 2026 will codify the DOL's 2018 FMLA job protections and prohibit insurers from discriminating against living donors.

The 2026 KidneyVoter™ campaign followed AAKP's bipartisan All Kidney Policy is Local™ national campaign, which connected patients, organ donors, and caregivers with U.S. Congressional leaders in their home district offices and online during the 2026 Congressional summer recess. Since 2025, the campaign has resulted in over 300 targeted legislative and policy meetings with top Congressional decision-makers. Both the KidneyVoter™ and the All Kidney Policy is Local™ campaigns are central elements of AAKP's Decade of the Kidney™ initiative, which supports kidney care innovation and implementation of the larger national kidney policy goals first outlined in the historic, bipartisan 2019 Executive Order on Advancing Kidney Health. AAKP provides advocacy skills and social media training for patients and organ donors through its Center for Patient Engagement and Advocacy and through its National Patient Meeting with a faculty of allied government affairs and political experts.

Follow AAKP on social media at @kidneypatient on Facebook, @kidneypatients on X, and @kidneypatients on Instagram, and visit http://www.aakp.org for more information. AAKP patient advocates advance bipartisan kidney policy including: passage of the bipartisan law modernizing the Organ Procurement and Transplantation Network (OPTN) (2023); lifetime transplant drug coverage for kidney patients (2020); the historic Executive Order on Advancing American Kidney Health signed by President Donald Trump (2019); job protections for living organ donors under the Family Medical Leave Act (FMLA) via the U.S. Department of Labor (2018); and Congressional approval of HIV positive organ transplants for HIV positive patients (2013).

MEDIACONTACT:

Brendan LaCivita

National and Medical Media Specialist

[email protected]

(813) 906-7740

SOURCE American Association of Kidney Patients

Share this article

Alphabet Inc. (GOOGL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM TOWNSHIP, Pa., Oct. 9, 2026/PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Alphabet Inc.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ALPHABET INC. (GOOGL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 1, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?

The complaint filed in this class action alleges that between May 19, 2026 and July 16, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) that the Gemini 3.5 Pro was delivering disappointing training results; (2) that, as a result, the launch of Gemini 3.5 Pro would be significantly delayed; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:

Howard G. Smith, Esq.,

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Call us at: (215) 638-4847

Email us at: [email protected],

Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Law Offices of Howard G. Smith

Howard G. Smith, Esquire

215-638-4847

[email protected]

www.howardsmithlaw.com

SOURCE Law Offices of Howard G. Smith

Share this article

LOS ANGELES, Oct. 9, 2026/PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Unicycive Therapeutics, Inc.

IF YOU SUFFERED A LOSS ON YOUR UNICYCIVE THERAPEUTICS, INC. INVESTMENTS, CLICK HERE BEFORE NOVEMBER 2, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed in this class action alleges that between December 29, 2025 and June 29, 2026, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) that, as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies; (3) that there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) that, as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What's The Next Step?

Glancy Prongay Wolke & Rotter LLP is a leading national shareholder rights law firm, ready to assist you in potentially pursuing claims to recover your loss.

If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. Please contact us to learn more about your rights and interests by clicking here, by email ([email protected]), or by telephone at 310-201-9150 (Toll-Free: 888-773-9224).

You may retain counsel of your choice. If you bought securities during the class period, you may take no action and remain an absent class member. No class has been certified yet.

Why Glancy Prongay Wolke & Rotter LLP?

GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm's recent successes, GPWR was named one of Law360's Securities Groups of the Year and ranked 2nd in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. Prior results do not guarantee a similar outcome.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Glancy Prongay Wolke & Rotter LLP,

1925 Century Park East, Suite 2100,

Los Angeles, CA 90067

Charles H. Linehan

Email: [email protected]

Telephone: 310-201-9150

Toll-Free: 888-773-9224

Visit our website at: www.glancylaw.com.

SOURCE Glancy Prongay Wolke & Rotter LLP

Share this article

Siteimprove Named a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Accessibility

Recognized for Completeness of Vision and Ability to Execute

COPENHAGEN, Denmark, Oct. 9, 2026 /PRNewswire/ -- We are excited to share that Siteimprove has been recognized as a Leader in the 2026 Gartner Magic Quadrant for Digital Accessibility.

"We're proud to be named a Leader in the 2026 Gartner® Magic Quadrant™ for Digital Accessibility. We built Siteimprove.ai for the way digital teams compete today: one agentic content intelligence platform unifying accessibility, analytics, SEO/AEO, and content strategy, extended into Claude, VS Code, Lovable, and Figma," said Nayaki Nayyar, CEO of Siteimprove.

Get your complimentary copy of the report here.

Gartner delivers actionable, objective insight to executives and their teams. Its expert guidance and tools enable faster, smarter decisions and stronger performance on an organization's mission-critical priorities.

The Gartner Magic Quadrant evaluates vendors based on their Ability to Execute and Completeness of Vision. We are honored to be included among the recognized vendors in this important report. Learn more about the Magic Quadrant.

Report citation

Gartner, Magic Quadrant for Digital Accessibility, Brent Stewart, Nabeeha Ahmed, Paige Kirk, Sarah Baumunk, 6 October 2026

Disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally. MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved.

Media Contact:

Emily Degnan

[email protected]

Share this article

RESTON, Va., Oct. 9, 2026 /PRNewswire/ -- General Dynamics (NYSE: GD) will webcast its third-quarter financial results conference call on Friday, October 30, beginning at 9 a.m. EDT.

The live webcast of the conference call will be available at www.gd.com. A replay will be available shortly after the live presentation.

More information about General Dynamics is available at www.gd.com.

SOURCE General Dynamics

Share this article

Century City Psychiatry, a physician-owned outpatient psychiatry practice in Los Angeles, offers specialized, individualized outpatient treatment for adults who want to stop using kratom, kratom extracts, or concentrated 7-hydroxymitragynine (7-OH) products. Developed under the clinical leadership of founder and board-certified psychiatrist Dr. Mike Mah, the program pairs medical support with care for the anxiety, depression, sleep difficulties, and other conditions that often accompany kratom use.

LOS ANGELES, Oct. 9, 2026 /PRNewswire/ -- Century City Psychiatry, a physician-owned outpatient psychiatry practice in Los Angeles, is responding to a growing public-health concern with specialized outpatient care for kratom and 7-OH dependence. The program, described on the practice's Kratom and 7-OH Dependence page, is designed for adults who use traditional leaf kratom, kratom extracts, or concentrated 7-OH tablets, shots, and extracts and are ready to stop.

Kratom, the leaf of the Southeast Asian tree Mitragyna speciosa, has been sold in the United States for years as a powder, capsule, or tea. More recently, a different category of product containing concentrated 7-OH has appeared in gas stations, smoke shops, and online stores, often marketed as a natural wellness supplement and frequently without clear labeling of its 7-OH content. Although 7-OH occurs only in trace amounts in the natural leaf, it acts on the same brain receptors as prescription opioids, and people who use concentrated products regularly can develop physical dependence and significant withdrawal symptoms. In July 2026, the U.S. Drug Enforcement Administration announced its intent to temporarily place 7-OH in Schedule I of the Controlled Substances Act, citing the proliferation of concentrated commercial products. The regulatory landscape around these products continues to evolve.

Many people who develop kratom or 7-OH dependence find themselves caught in a gap in care. Addiction-medicine clinics can feel intimidating, residential programs are impractical for working adults, and many general psychiatric practices do not treat substance use disorders. Patients are often surprised to learn what they were taking, and shame about being unable to stop can keep them from asking for help. Century City Psychiatry's program is built to offer a confidential, outpatient alternative that fits into the lives of people with careers and family responsibilities.

The program was developed under the clinical leadership of Dr. Mike Mah, founder and clinical director of Century City Psychiatry. Dr. Mah is board-certified by the American Board of Psychiatry and Neurology, earned his medical degree from UC Irvine, and completed his psychiatry residency at UCLA and the West Los Angeles VA. He designs the practice's treatment protocols and supervises a team of psychiatric nurse practitioners and prescribing clinicians who provide day-to-day patient care.

Each treatment plan is individualized around what a patient is using, how much, and the goals the patient brings to the first visit. Care begins with a comprehensive evaluation of kratom or 7-OH use alongside a full medical and psychiatric history. For patients with moderate to severe dependence, particularly with 7-OH, clinicians may discuss medication support, including buprenorphine, an FDA-approved medication for opioid use disorder, introduced gradually through a micro-induction approach rather than requiring a patient to be in full withdrawal first. For patients using smaller amounts of leaf kratom, a structured taper supported by non-addictive medications may be appropriate. Because severe dependence cannot always be managed safely in an outpatient setting, some patients may need a higher level of care, such as medically supervised detox or residential treatment, and the practice helps coordinate those referrals when needed. Treatment decisions are always made together with a clinician.

Because many patients began using kratom to manage anxiety, depression, ADHD, chronic pain, or poor sleep, treatment of these underlying conditions is a central part of care. The practice coordinates with Los Angeles therapists who specialize in substance use, and most patients continue follow-up care for several months to a year as stability builds. Treatment records are protected under HIPAA and additional federal rules specific to substance use disorder care. As an insurance-based group practice, Century City Psychiatry accepts many major commercial insurance plans, with specific coverage confirmed at intake.

"Most people who develop kratom dependence are not who you picture when you hear the word 'addiction,'" said Dr. Mah. "They are working adults who started using to manage anxiety, pain, or sleep, and many had no idea how strong some of these products had become. Treating those underlying conditions is easy to miss, and it is central to how we built this program. With the right medical support and a thoughtful, gradual start, withdrawal does not have to be something people white-knuckle alone. Reaching out is often the hardest step, and we want patients and their families to know that individualized, confidential care is available."

Information about kratom and 7-OH treatment is educational and is not medical advice. Anyone experiencing a medical emergency should call 911, and anyone in crisis can call or text 988 to reach the Suicide and Crisis Lifeline.

More About Century City Psychiatry

Century City Psychiatry is a physician-owned outpatient psychiatry practice in Los Angeles founded by Dr. Mike Mah, a board-certified psychiatrist who serves as the practice's clinical director. The insurance-based group practice provides psychiatric evaluation, medication management, deprescribing, ongoing psychiatric care, second opinions, and care coordination, with in-person and secure virtual visits available. The practice treats adults with anxiety disorders, mood disorders, ADHD, insomnia, trauma-related conditions, and substance use and dual-diagnosis concerns, including kratom and 7-OH dependence, with an emphasis on evidence-based, physician-directed care.

Century City Psychiatry is located at 10323 Santa Monica Blvd., #108A, Los Angeles, CA 90025. For more information or to schedule a confidential evaluation, please call (310) 340-0089 or visit www.centurycitypsychiatry.com.

Media Contact

Century City Psychiatry

10323 Santa Monica Blvd., #108A, Los Angeles, CA 90025

(310) 340-0089

https://www.centurycitypsychiatry.com

SOURCE Century City Psychiatry

Share this article

JERSEY CITY, N.J., Oct. 9, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, has closed its previously announced registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.

Additionally, the Company closed its previously announced concurrent private placement of warrants to purchase up to an aggregate 980,072 shares of common stock at an exercise price of $6.122 per share. The pre-funded warrants have an exercise price of $0.007 per share of common stock, and the warrants have an exercise price of $6.122 per share, will be exercisable following stockholder approval, and will expire five years from the date of stockholder approval.

WallachBeth Capital, LLC acted as sole placement agent for the offering.

The gross proceeds to the Company from the offering were approximately $4 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital, to support expected growing sales for CyPath® Lung, its noninvasive test for lung cancer, and general corporate purposes.

The common stock described above was offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-275608) previously filed with the U.S. Securities and Exchange Commission ("SEC"), under the Securities Act of 1933, as amended (the "Securities Act"), and declared effective by the SEC on November 27, 2023. The offering of the shares of common stock is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement describing the terms of the registered direct offering and accompanying prospectus has been filed with the SEC. Electronic copies of the prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at https://www.sec.gov or by contacting WallachBeth Capital, LLC, via email at [email protected], by calling +1-646-237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About WallachBeth Capital LLC:

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations are discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

SOURCE WallachBeth Capital LLC

Share this article

/C O R R E C T I O N -- The Home Depot/

In the news release, The Home Depot Announces 2026 Innovation Award Winners, issued 07-Oct-2026 by The Home Depot over PR Newswire, we are advised by the company that one of the listed finalists has been updated. The complete, corrected release follows:

The Home Depot Announces 2026 Innovation Award Winners

In every space in the home, award-winning products take the friction out of DIY and elevate home improvement projects for customers

- Annual Recognition Program: The Home Depot's 2026 Innovation Awards recognize standout products that elevate home renovation for DIY and Pro customers by making projects faster, easier, and more efficient.

- Winner: Hampton Bay/Glacier Bay Ready to Assemble Cabinets with ClickReady Technology earned top honors for tool-free, snap-together assembly that simplifies kitchen renovations.

- Runners-Up: The Even Embers Santa Maria Grill (first runner-up) and USG UltraLight Tough Gypsum Sheetrock Panels (second runner-up) were recognized for backyard live-fire cooking and lightweight job-site durability.

- These breakthrough products can empower DIYers and Pros alike to complete projects with greater confidence, in less time, and all without compromising quality.

ATLANTA, Oct. 7, 2026 /PRNewswire/ -- The Home Depot announced its 2026 Innovation Awards winners at its Annual Supplier Partnership Meeting, recognizing products across various home improvement categories spanning from the backyard to the kitchen.

The winners of the 2026 Innovation Awards are:

- Winner: Hampton Bay/Glacier Bay Ready to Assemble Cabinets with ClickReady Technology make it easy to create your dream kitchen with confidence. Designed to simplify installation, ClickReady technology allows pieces to snap together effortlessly with zero tools required, helping customers spend less time assembling and more time gathering in the kitchen with family and friends. Available in a wide range of shapes, sizes and styles, the cabinets take the hassle out of kitchen renovations.

- First Runner Up: Even Embers Santa Maria Grill makes cooking for a crowd delicious and fun. With over 1,000 square inches of cooking space and an adjustable crank system for precise heat control, customers can grill everything from steaks to fruit and vegetables all at once and transform their outdoor cooking spaces with the excitement of live-fire cooking.

- Second Runner Up: USG UltraLight Tough Gypsum Sheetrock Panels are lighter than the industry average and much easier to lift, carry and install, saving Pros time and money by making their jobs faster and easier.

"Our customers count on The Home Depot for the best products to get the job done," said Billy Bastek, executive vice president of merchandising at The Home Depot. "Our supplier partners continue to raise the bar, bringing us innovative products that save our Pros and DIYers time and money and make home improvement more attainable for everyone."

In addition to the winner and runners-up, The Home Depot also recognized several finalists for their dedication to innovation:

- Deckorators Summit Composite Deck Boards are highly durable and resistant to outdoor elements.

- Kibosh 3/4 in. Emergency Pipe Repair is a sturdy, reuseable clamp that can repair perforated copper, plastic or metal pipes in a pinch.

- Kidde Wire Free RF Interconnected Smoke and Smoke + Carbon Monoxide Detectors connect wirelessly around the home for simultaneous voice alerts.

- Clopay Avante Garage Door features glass panels that switch from clear to opaque at the click of a button, alongside a sleek design that hides exposed hinges and tracks.

- Lifeproof Polished Tile Look Vinyl Planks withstand life's spills, scuffs and scratches, with a sleek, modern look and without traditional grout application.

- Hampton Bay Lauder and Rosemont Solar Path Light offers adjustable lumens to elevate the ambience and safety of your driveway with no wiring needed.

- Husky & NEBO Lighting Innovations offer rechargeable flashlights, floodlights and headlamps to brighten any kind of project.

- Milwaukee M12 Fuel Ratchets offer power and speed for removing and installing fasteners with a comfortable, contoured grip.

- HDX & Husky Totes make storage and organization a breeze for any occasion. With sizes ranging from 2.5-quarts up to 170-gallons, you can store just about anything, even The Home Depot's 12 FT SKELLY™ Skeleton.

- Ryobi High Flow Automotive Pressure Washer delivers high-powered performance to clean vehicles, driveways and patios with ease.

- Diablo Wood Demon Circular Saw Blade offers exceptional precision and ultra-fine finishes compared to standard blades, saving time for both professional carpenters and DIYers.

- Dewalt Atomic Compact Grinders are engineered for maximum control and maneuverability to tackle tough metalworking jobs in tight spaces.

- Bella Vita Easy-Care Begonia Flowers bring vibrant, low-maintenance beauty to your home or garden all season long. They are designed for exceptional longevity and can be found in stores and online seasonally.

The Home Depot recognized outstanding supplier Partner of the Year recipients in each merchandising category:

- Appliances: Ryobi

- Bath: Kohler

- Building Materials: Quikrete

- Electrical: Titan3

- Flooring: Halstead/Vertex

- Hardware: Milwaukee

- Kitchen & Blinds: Levolor

- Lighting: King of Fans

- Lumber: Trex company

- Millwork: Steves & Sons

- Outdoor Living & Cleaning: Nexgrill

- Outdoor Garden: Grand Flower Growers

- Paint: ICON Protection

- Plumbing: RectorSeal

- Power Tools: TTI

- Storage & Organization: Kreate

The Home Depot also honored Back to the Roots as Environmental Partner of the Year, Delta as Interconnected Partner of the Year, and BEHR as Marketing Partner of the Year.

To learn more about this year's Innovation Award honorees, visit www.homedepot.com/innovation.

ABOUT THE HOME DEPOT

The Home Depot is the world's largest home improvement specialty retailer. At the end of the second quarter of fiscal 2026, the company operated a total of 2,364 retail stores and over 1,340 SRS locations across all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The Company employs over 470,000 associates. The Home Depot's stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor's 500 index.

SOURCE The Home Depot

Share this article